Camrelizumab combined with dose-dense neoadjuvant chemotherapy in triple-negative breast cancer: first results of the prospective CAMELLA study

Triple-negative breast cancer (TNBC) accounts for approximately 15 % of all breast cancer cases and is characterised by an aggressive course and an increased risk of early relapse. Pathological complete response (pCR) after neoadjuvant treatment is associated with improved long-term outcome. The addition of PD‑1 inhibitors to neoadjuvant chemotherapy increases pCR and improves survival, making chemoimmunotherapy a treatment option for early and locally advanced TNBC. The review section covers KEYNOTE‑522, GeparNuevo and CamRelief and the rationale for camrelizumab in the Russian healthcare setting. CAMELLA (NCT07107217) is a prospective, open-label, non-randomised multicentre phase II study combining camrelizumab with dose-dense doxorubicin/ cyclophosphamide followed by weekly paclitaxel/carboplatin. This interim single-centre analysis includes 25 evaluable patients. Nineteen patients underwent surgery and definitive pathological results were available for 16. pCR was achieved in 12 of 16 patients (75.0 %; exact 95 % CI 47.6–92.7), RCB-I in 3 (18.8 %), and RCB-II in 1 (6.3 %); the combined RCB 0–I rate was 93.8 % (15/16; exact 95 % CI 69.8–99.8). Among 13 initially node-positive patients with pathology available, nodal pCR was observed in 12 (92.3 %). Cohort-level administered-dose ratios were 100.0 % for doxorubicin and cyclophosphamide, 97.5 % for paclitaxel, 81.2 % for carboplatin, and 94.5 % for camrelizumab; time-adjusted relative dose intensities were 94.4 %, 94.4 %, 90.5 %, 75.9 %, and 87.4 %, respectively. Grade 3–4 neutropenia was documented in 9/25 (36.0 %) patients, reactive cutaneous capillary endothelial proliferation in 23/25 (92.0 %), and grade 2 hypothyroidism in 10/25 (40.0 %). Four patients discontinued the second chemotherapy block early due to toxicity and one withdrew from further chemotherapy. These data reproduce the results of the CamRelief registration trial in Russian clinical practice and with a dose-dense chemotherapy backbone.

Authors

Institutions

Publication Details

Journal
Medical alphabet
Published
2026-11-15
DOI
https://doi.org/10.33667/2078-5631-2026-27-7-15
Primary Topic
Breast Cancer Treatment Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Camrelizumab combined with dose-dense neoadjuvant chemotherapy in triple-negative breast cancer: first results of the prospective CAMELLA study

Елена Владимировна Артамонова, M. V. Khoroshilov, Alexander Nikolaevich Petrovsky, Elena Igorevna Kovalenko et al.
Medical alphabet
Breast Cancer Treatment Studies
article

Camrelizumab combined with dose-dense neoadjuvant chemotherapy in triple-negative breast cancer: first results of the prospective CAMELLA study

Елена Владимировна Артамонова, M. V. Khoroshilov, Alexander Nikolaevich Petrovsky, Elena Igorevna Kovalenko, Татьяна Александровна Титова
article en

Abstract

Triple-negative breast cancer (TNBC) accounts for approximately 15 % of all breast cancer cases and is characterised by an aggressive course and an increased risk of early relapse. Pathological complete response (pCR) after neoadjuvant treatment is associated with improved long-term outcome. The addition of PD‑1 inhibitors to neoadjuvant chemotherapy increases pCR and improves survival, making chemoimmunotherapy a treatment option for early and locally advanced TNBC. The review section covers KEYNOTE‑522, GeparNuevo and CamRelief and the rationale for camrelizumab in the Russian healthcare setting. CAMELLA (NCT07107217) is a prospective, open-label, non-randomised multicentre phase II study combining camrelizumab with dose-dense doxorubicin/ cyclophosphamide followed by weekly paclitaxel/carboplatin. This interim single-centre analysis includes 25 evaluable patients. Nineteen patients underwent surgery and definitive pathological results were available for 16. pCR was achieved in 12 of 16 patients (75.0 %; exact 95 % CI 47.6–92.7), RCB-I in 3 (18.8 %), and RCB-II in 1 (6.3 %); the combined RCB 0–I rate was 93.8 % (15/16; exact 95 % CI 69.8–99.8). Among 13 initially node-positive patients with pathology available, nodal pCR was observed in 12 (92.3 %). Cohort-level administered-dose ratios were 100.0 % for doxorubicin and cyclophosphamide, 97.5 % for paclitaxel, 81.2 % for carboplatin, and 94.5 % for camrelizumab; time-adjusted relative dose intensities were 94.4 %, 94.4 %, 90.5 %, 75.9 %, and 87.4 %, respectively. Grade 3–4 neutropenia was documented in 9/25 (36.0 %) patients, reactive cutaneous capillary endothelial proliferation in 23/25 (92.0 %), and grade 2 hypothyroidism in 10/25 (40.0 %). Four patients discontinued the second chemotherapy block early due to toxicity and one withdrew from further chemotherapy. These data reproduce the results of the CamRelief registration trial in Russian clinical practice and with a dose-dense chemotherapy backbone.

Medical alphabet(27)
Sechenov University (RU), Pirogov Russian National Research Medical University (RU), Russian Cancer Research Center NN Blokhin (RU), Moscow Regional Scientific Research Clinical Institute. MF Vladimirsky (RU), Ministry of Health of the Russian Federation (RU)
Breast Cancer Treatment Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon